Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

NCT07294547 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplantation, Cytomegalovirus Infections
EBV Infection
Antiviral Prophylaxis

Interventions

DRUG: Valacyclovir (Valtrex)
DRUG: Valganciclovir (Valcyte)

Sponsor

National Taiwan University Hospital